METHOD FOR TREATING MEMBRANOUS NEPHROPATHY WITH TACI-FC FUSION PROTEIN
Summary
USPTO published patent application US20260098077A1 for a method of treating membranous nephropathy using TACI-Fc fusion protein. The application, filed September 28, 2023, discloses dosage schemes, administration intervals, and clinical efficacy data showing good safety profiles in patients.
What changed
USPTO published patent application US20260098077A1 disclosing a method for treating membranous nephropathy using TACI-Fc fusion protein. The application covers the drug composition, dosage regimen, administration intervals, and clinical data demonstrating therapeutic efficacy and safety in patients.
Pharmaceutical and biotechnology companies developing treatments for membranous nephropathy or other autoimmune kidney diseases should monitor this application for potential licensing opportunities or freedom-to-operate considerations. The TACI-Fc fusion protein approach represents a novel biologic therapy targeting B-cell mediated autoimmune conditions affecting kidney function.
What to do next
- Monitor patent prosecution status for potential licensing opportunities
- Review freedom-to-operate if developing similar nephropathy treatments
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD FOR TREATING MEMBRANOUS NEPHROPATHY WITH TACI-FC FUSION PROTEIN
Application US20260098077A1 Kind: A1 Apr 09, 2026
Inventors
Xiangdong YANG, Ling GUO, Dengren LI, Jianmin FANG, Wenxiang WANG
Abstract
The present disclosure relates to a drug, a dosage scheme, an administration interval, and an administration mode for treating membranous nephropathy with a TACI-Fc fusion protein. Results show that the TACI-Fc fusion protein provided by the present disclosure shows relatively good clinical curative effect and good safety in the process of treating a patient with membranous nephropathy.
CPC Classifications
C07K 14/70578 A61K 9/0019 A61P 13/12 A61P 37/06 A61K 38/00 C07K 2319/30
Filing Date
2023-09-28
Application No.
19114798
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.